Drugs / AAV9/CLN7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04737460 | May 2021 → Feb 2028 expected | neuronal ceroid lipofuscinosis 7 | Benjamin Greenberg | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV9/CLN7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04737460 ↗ |
| Action | Restore | “expresses the fully functional form of MFSD8” NCT04737460 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV9-based gene therapy vector” NCT04737460 ↗ |
| Route | Intrathecal | “administered intrathecally into the lumbar spinal cord region” NCT04737460 ↗ |
| Target | MFSD8 | “expresses the fully functional form of MFSD8” NCT04737460 ↗ |